Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis

Investigational New Drugs

Volumn 26, Issue 1, 2008, Pages 13-24

  Dudek, Arkadiusz Z ^a   Zwolak, Pawel ^a   Jasinski, Piotr ^a   Terai, Kaoru ^a   Gallus, Nathan J ^b   Ericson, Marna E ^b   Farassati, Faris ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone cancer pain; Enzastaurin; Metastatic bone cancer; Protein kinase C beta; Radiation; Ras inhibition

Indexed keywords

CASPASE; ENZASTAURIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA INHIBITOR; RAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CONTROL; CANCER PAIN; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; INDOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; PAIN; PROTEIN KINASE C; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 38149119710     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9079-y     Document Type: Article

References (34)

1. Black JD (2000) Protein kinase C-mediated regulation of the cell cycle. Front Biosci 5:D406-D423
2. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332(Pt 2):281-292
3. Kawakami Y, Nishimoto H, Kitaura J et al (2004) Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 279(46):47720-47725
4. Goode N, Hughes K, Woodgett JR, Parker PJ (1992) Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 267(24):16878-16882
5. Kolch W, Heidecker G, Kochs G et al (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364(6434):249-252
6. Liu JF, Crepin M, Liu JM, Barritault D, Ledoux D (2002) FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 293(4):1174-1182
7. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP (2004) Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 279(21):22118-22123
8. Lahn M, Kohler G, Sundell K et al (2004) Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67(1):1-10
9. Hoey RP, Sanderson C, Iddon J, Brady G, Bundred NJ, Anderson NG (2003) The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer 88(4):567-573
10. Mihai R, Stevens J, McKinney C, Ibrahim NB (2006) Expression of the calcium receptor in human breast cancer-a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 32(5):511-515
11. Tfelt-Hansen J, MacLeod RJ, Chattopadhyay N et al (2003) Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol 285(2):E329-E337
12. Graff JR, McNulty AM, Hanna KR et al (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65(16):7462-7469
13. Keyes KA, Mann L, Sherman M et al (2004) LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53(2):133-140
14. Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV (2006) A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Res 66(21):10434-10438
15. Goblirsch MJ, Zwolak P, Clohisy DR (2005) Advances in understanding bone cancer pain. J Cell Biochem 96(4):682-688
16. Ewing P, Wilke A, Brockhoff G et al (2003) Isolation and transplantation of allogeneic pulmonary endothelium derived from GFP transgenic mice. J Immunol Methods 283(1-2):307-315
17. Dong QG, Bernasconi S, Lostaglio S et al (1997) A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 17(8):1599-1604
18. Sevcik MA, Ghilardi JR, Peters CM et al (2005) Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115(1-2):128-141
19. Honore P, Luger NM, Sabino MA et al (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6(5):521-528
20. Goblirsch M, Mathews W, Lynch C et al (2004) Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 161(2):228-234
21. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63(11):2940-2947
22. Lees RL, Heersche JN (1999) Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size. J Bone Miner Res 14(6):937-945
23. Sabino MA, Ghilardi JR, Jongen JL et al (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62(24):7343-7349
24. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ (1998) Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90(6):447-454
25. Tabatabai G, Frank B, Wick A, Lemke D, von Kurthy G, Obermuller U, Heckl S, Christ G, Weller M, Wick W (2007) Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 61(2):153-161, Feb
26. Querfeld C, Rizvi MA, Kuzel TM et al (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126(7):1641-1647
27. Rizvi MA, Ghias K, Davies KM et al (2006) Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 5(7):1783-1789
28. Kim IA, Bae SS, Fernandes A et al (2005) Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65(17):7902-7910
29. Lee SW, Kwak HB, Chung WJ, Cheong H, Kim HH, Lee ZH (2003) Participation of protein kinase C beta in osteoclast differentiation and function. Bone 32(3):217-227
30. Rousselle AV, Heymann D (2002) Osteoclastic acidification pathways during bone resorption. Bone 30(4):533-540
31. Mach DB, Rogers SD, Sabino MC et al (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113(1):155-166
32. Olson TH, Riedl MS, Vulchanova L, Ortiz-Gonzalez XR, Elde R (1998) An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport 9(6):1109-1113
33. Carducci MA, Musib L, Kies MS et al (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24(25):4092-4099, Sep 1
34. Rademaker-Lakhai JM, Beerepoot LV, Mehra N et al (2007) Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C {beta}-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 13(15):4474-4481, Aug 1